Get started
Author

Bénédicte Gelas‐Dore

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
2018 · Emmanuel Bachy, Matthew J. Maurer, et al. · Blood · 212
PDF
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
2015 · Robert Kridel, Luc Xerri, et al. · Clinical Cancer Research · 125
Evaluation of previously nonscreened hereditary hemorrhagic telangiectasia patients shows frequent liver involvement and early cardiac consequences
2008 · Rodica Gincul, Gaetan Lesca, et al. · Hepatology · 53
PDF
Low Skeletal Muscle Mass and Risk of Functional Decline in Elderly Community-Dwelling Women: The Prospective EPIDOS Study
2013 · Isabelle Amigues, Anne-Marie Schott, et al. · Journal of the American Medical Directors Association · 48
Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network
2016 · Sylvain Choquet, Caroline Houillier, et al. · Blood · 37
Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients
2017 · Luc Xerri, Sarah Huet, et al. · Human Pathology · 29
Are Patients With Self-Inflicted Injuries More Likely to Die?
2007 · Jean-Stephane David, Benedicte Gelas-Dore, et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 20
S tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: A n exploratory analysis of the PRIMA cohort study
2016 · Emmanuel Bachy, Jane A. Estell, et al. · American Journal of Hematology · 10
PDF
Ibrutinib in Relapse or Refractory Primary Cns and Vitreo‐retinal Lymphoma. Results of the Primary End‐point of the Iloc Phase Ii Study From the Lysa and the French Loc Network.
2017 · C. Soussain, S. Choquet, et al. · Hematological Oncology · 5
PDF
Estimates of the Number of Cancer Patients Hospitalized in a Geographic Area Using Claims Data without a Unique Personal Identifier
2006 · C. M. Couris, C. Gutknecht, et al. · Methods of Information in Medicine · 4
L'hyperdivergence est-elle une contre-indication dans le traitement précoce des classes II ?
2008 · Sarah Gebeile-Chauty, Anne-Marie Schott, et al. · L Orthodontie Française · 3
[Analysis of the medical activity related to cancer in a network of multidisciplinary hospitals using claims databases, the reseau Concorde Oncology Network].
2005 · Anne-Marie Schott, Touria Hajri, et al. · PubMed · 3
La contention est-elle justifiée après traitement interceptif de classe II ?
2009 · Sarah Gebeile-Chauty, Caroline Akharzouz, et al. · L Orthodontie Française · 2
Supplemental Figures 1-8 from The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
2023 · Robert Kridel, Luc Xerri, et al.
PDF
Data from The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
2023 · Robert Kridel, Luc Xerri, et al.
Data from The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
2023 · Robert Kridel, Luc Xerri, et al.
Supplemental Figures 1-8 from The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
2023 · Robert Kridel, Luc Xerri, et al.
Indices anthropométriques et incapacité fonctionnelle chez le sujet âgé : l’étude EPIDOS
2009 · M. Amine, F. Canouï-Poitrine, et al. · Revue d Épidémiologie et de Santé Publique
Works count: 18
Citation count: 551
H-index: 8
I10-index: 8
Year
Topic
Type